Just as pandemic-related supply chain turbulence appeared to be settling, the Russia-Ukraine conflict has thrown up new challenges, with experts now also drawing attention to the possible commodities-related impact on medical products.
USP Exec On Onshoring, Impact Of War-Fueled Metals Turbulence On Pharma
US Pharmacopeia senior director, regional program operations, South Asia, Matruprasad Priyadarshi, discusses with Scrip the need to assess onshoring on a medicine-by-medicine basis and the organization’s efforts to support quality assessments for new mRNA-based therapies. The executive also flags up new trouble spots as metals such as aluminium and nickel, used in medical products and currently witnessing price surges, are mined in the war-torn Russia-Ukraine region.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.